Journal article
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).
Abstract
2534
Background: Preclinical data suggest that combined Ang1/2 and mTOR blockade has synergistic anti-cancer activity. The combination of Tr (inhibits angiogenesis by preventing interaction of Ang1/2 with Tie2) with the mTOR inhibitor T was evaluated in pts with advanced solid tumors to determine safety, tolerability, maximum tolerated dose (MTD), pharmacodynamics and preliminary antitumor activity. Methods: Pts were enrolled …
Authors
Tan DSP; Kollmannsberger CK; Hotte SJ; Cescon DW; Diaz-Padilla I; Hedley DW; Renouf DJ; Razak ARA; Gelmon KA; Hirte HW
Journal
Journal of Clinical Oncology, Vol. 31, No. 15_suppl, pp. 2534–2534
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.2534
ISSN
0732-183X